Ken Griffin Cassava Sciences Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $4.41 Million - $16.2 Million	460,600 Added 691.59%	527,200 $15.5 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $69,160 - $146,216	5,600 Added 9.18%	66,600 $822,000
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $5.43 Million - $7.77 Million	-294,200 Reduced 82.83%	61,000 $1.24 Million
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $1.39 Million - $3.3 Million	-109,600 Reduced 23.58%	355,200 $8 Million
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $1.5 Million - $2.28 Million	90,200 Added 24.08%	464,800 $7.73 Million
Q2 2023 Aug 14, 2023	SELL	$21.59 - $27.88 $1.31 Million - $1.7 Million	-60,900 Reduced 13.98%	374,600 $9.19 Million
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $6.69 Million - $10.4 Million	-285,200 Reduced 39.57%	435,500 $10.5 Million
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $11.5 Million - $18.2 Million	-412,700 Reduced 36.41%	720,700 $21.3 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $3.63 Million - $11.4 Million	222,400 Added 24.41%	1,133,400 $47.4 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $93.8M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.